Objectives: To assess the effectiveness and safety of Chinese medicinal herbs for treating uncomplicated acute bronchitis.
A cute bronchitis is one of the most common diagnoses made by primary care physicians. [1] [2] [3] This condition accounted for approximately 2.5 million visits to U.S. physicians in 1998. 4 It consistently ranks as one of the top 10 diagnoses for which patients seek medical care, with cough being the most frequently mentioned symptom. 4 During each episode, patients receive an average of two prescriptions and miss 2 to 3 days of work. 5 Viruses are the most common cause of the bronchial inflammation associated with acute bronchitis in otherwise healthy adults. Only a small proportion of acute bronchitis infections are caused by non-viral agents, with the most common organism being Mycoplasma pneumoniae (M. pneumoniae). [6] [7] [8] Study findings suggest that Chlamydia pneumoniae (C. pneumoniae) also may cause acute bronchitis. 10, 11 Antibiotics are the predominant therapy offered to patients with acute bronchitis. 11 However, there is evidence for the effectiveness of antibiotics over placebo of modest benefit only. 12 Symptomatic treatments have even less evidence, and include: antitussives for cough; expectorants for sputum too viscous to expectorate; bronchodilators for cough associated with any associated asthma; and antipyretic analgesics for fever.
In China, many physicians believe that herbs are effective for acute bronchitis. Some Chinese herbs have been demonstrated to be antiviral, antiasthmatic, antitussive, and fever relieving. For example, Radix scutellariae has antiphlogistic effects 13 ; Radix glycyrrhizae has expectorant effects 14 ; and Folium perillae has antitussive effects. 15 Herbs for various symptoms or causes are combined in set quantities as a basic prescription to treat acute bronchitis.
Natural medicinal herbs are a potential drug resource. Therefore, a systematic review of the evidence as to whether or not these medicinal herbs are effective for acute bronchitis.
METHODS

Criteria for considering studies for this review Types of studies. Randomised controlled trials (RCTs).
Types of participants.
Trials which included patients of either gender or any age with a clinical syndrome of cough and productive sputum or a physician's diagnosis of acute bronchitis were included. Trials which included patients with pre-existing chronic bronchitis (that is, acute exacerbation of chronic bronchitis) or other infectious diseases and fever-causing diseases were not included.
Types of interventions.
Studies comparing any Chinese herbal combination to placebo, antibiotics, or other routine care were acceptable.
Types of outcome measures. We included outcomes of clinical importance. These outcomes were as follows:
1. Time to resolution of cough, sputum production, and activity limitations 2. Proportions of patients with cough, night cough, productive cough, activity limitations, or abnormal lung examination at a designated follow-up visit 3. Global assessment of improvement by clinicians at follow-up 4. Adverse effects The search strategy defined by the Cochrane Collaboration and detailed in Appendix 5c of the Cochrane Reviewers' Handbook (Edition 4.2.2). 16 The search terms were bronchitis and Chinese herbs.
Data sources
We also searched databases of ongoing trials: Current Controlled Trials (www.controlled-trials.com) and the National Research Register (www.update-software.com/National/nrr-frame.html). We attempted to identify additional studies by searching the reference lists of relevant trials, reviews, conference proceedings, and journals. In particular, with respect to journals, we searched those not indexed in the electronic databases.
Methods of the review
Trials selection. Titles and abstracts were reviewed from articles found in the searches. Those that appeared eligible were retrieved as full text articles. The inclusion criteria were applied by two authors independently. Disagreements were resolved by consensus, and the authors of the trials were contacted for more details when needed.
Quality assessment of trials. Wei and Wu assessed methodological quality of each trial in terms of generation of allocation sequence, allocation concealment, blinding, and loss to follow-up. For each trial, we classed each quality component as "adequate," "inadequate," "unclear," or "not used," according to Schulz and Jadad 17, 18 and the Cochrane Reviewers' Handbook 4.2.2. After including all eligible studies in the primary analysis, we intended to conduct sensitivity analyses for each of the quality factors using the subgroups adequate, inadequate, or unclear.
Data extraction. Wei and Wu independently extracted data using a piloted data extraction form. We extracted data on study characteristics including methods, participants, interventions, and outcomes. We resolved any disagreements by referring to the trial report and through discussion. If data from the trial reports were insufficient or missing, we contacted the authors for additional information. If the authors could not be contacted, we allocated the study to the category "Studies awaiting assessment."
Where possible, we extracted data to allow an intentionto-treat analysis (the analysis should include all the participants in the groups to which they were originally randomly assigned). If the number randomised and the numbers analysed were inconsistent, we calculated the percentage lost to follow-up and reported this information separately. For binary outcomes, we recorded the number of participants experiencing the event in each group of the trial. For con-tinuous outcomes, for each group we extracted the arithmetic means and standard deviations.
Extraction was undertaken by one reviewer and checked by a second. Data entry into RevMan (free software downloadable from www.cc_ims.net/RevMan.download.htm) was double-checked.
Data analysis.
We had planned to include data with the same medicinal herbs in a meta-analysis. However, as none of the trials were similar in participants and/or interventions, we provided a summary of each trial.
If, in the future, enough suitable trials for meta-analysis become available, we will use the following approach.
The data will be dichotomised and expressed as relative ratio (RR).
Overall results will be calculated based on the randomeffects model. Heterogeneity will be tested for using the Chi square statistic with significance being set at a p-value less than 0.1 and I square more than 50%. Possible sources of heterogeneity will be assessed by sensitivity and subgroup analyses. Publication bias will be tested by using the funnel plot or other corrective analytical method, depending on the number of clinical trials included in the systematic review.
Description of studies
We found 30 clinical RCTs on the use of Chinese medicinal herbs for acute bronchitis, and 14 of these were included in the review (Table 1) . [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] In 12 of the excluded studies Chinese medicinal herbs were administered in both the intervention and control groups, which did not meet the intervention criteria. In the other four trials the methods of randomisation allocation were inadequate.
Designs of included studies. Details of the included studies are shown in Table 1 . All included studies were described as randomised controlled parallel trials. All studies mentioned "random allocation" but without an explanation of the randomisation method. None of the studies mentioned "blinding" or "allocation concealment." The duration of trials ranged from 2 to 14 days. All of the trials were conducted in China.
Participants of included studies. The number of participants in the studies ranged from 82 to 456, with a total of 2771. All the patients were diagnosed with acute bronchitis by physicians. Three trials [19] [20] [21] focused on adults aged over 16 years old, nine trials 22, 30 were limited to children aged below 14 years old, and the other two trials 31, 32 had no limitation on age.
In eight studies, 19, 20, [26] [27] [28] [29] [30] the duration of illness was not expressed clearly; and in six trials it ranged from 1 to 60 days. The baseline data were stated in all trials and the comparability was analysed.
Interventions. Twelve Chinese herbal preparations used for acute bronchitis were analysed. They were as follows: Tan Re Qing injection, 19 Dai Zhe Zhi Sou San, 31 E Shu You, 26 Zeng Xiao Zhi Ke He Ji, 20 Shi Wei Long Dan Hua Ke Li, 22, 23, 28 Shuang Huang Lian, 21 Xiao Er Xiao Ji Zhi Ke Kou Fu Ye, 25 "atomization of Yu Xing Cao injection", 27 Yu Xing Cao injection, 30 Jia Wei Zhi Sou San, 30 Zhi Sou San, 32 Zi Yi San Ye Shuang Hua Tang. 24 In seven trials 21, 22, [26] [27] [28] [29] [30] antibiotics were used in both the intervention and control groups. In three of these trials, 21, 26, 30 antibiotics, antitussives, expectorants, and bronchodilators were used in both intervention and control groups.
In three trials 25, 31, 32 Chinese herbal preparations were used in the intervention group and antibiotics plus expectorants and antitussives were used in the control group.
In four trials, 19, 20, 23, 24 Chinese herbal preparations were used in the intervention group and antibiotics used in the control group.
Outcome measures. The majority of trials used the physician's global assessment of improvement at follow-up; the timing of assessment varied from trial to trial. Two trials1 19, 22 evaluated the proportion of patients with a variety of improved signs and symptoms. Three trials 25, 27, 28 analysed the time to resolution of cough, rales, and fever. One trial 25 assessed the time to resolution of wheezing. One trial 19 evaluated the time to relief of cough and fever.
Methodological quality of included studies. All of the trials were randomised controlled trials comparing a preparation of Chinese medicinal herbs with "standard treatment." Seven of the trials used antibiotics in both groups. All of the studies mentioned random allocation but none of the trials clearly stated the randomisation method. None of the articles mentioned allocation concealment.
None of the studies mentioned either double-or singleblinding. Most preparations of Chinese medicinal herbs differ from Western medicine in terms of smell, taste, type, and colour. It was difficult, therefore, to use double blinding when administering the interventions. However, doubleblinding can be used for some dosage forms such as an injection or capsule.
None of the trials reported withdrawals or loss to followup.
None of the trials reported the methods to ensure compliance.
The similarity of comparison groups at baseline was reported in all trials based on age, gender, and disease duration at entry. Fig. 1) 1. Cough: Data from four trials showed that the duration of cough was shorter in the Chinese herbs group than in the control group. (mean duration 17 d) herba schizonepetae 9 g, swallowwort rhizome
RESULTS
Time to improvement of symptoms and signs (
General improvement: all manifestations resolved, but
Blinding not used.
9 g, aster root roasted 9 g, stemona root roasted relapsed once in a while during 14-day treatment 9 g, scutellaria root 9 g, platycodon root 6 g, Ineffective: no improvement with treatment of 14 days tangerine peel 6 g, fresh licorice root 6 g, decocted twice for 800 mL extract), 400 mL, bid pepperweed seed 6 g, decocted for 100 mL extract), 50 mL bid, 100 mL bid, or 100 mL tid 25 Time to resolution of cough was evaluated and showed a statistically significant decrease (WMD Ϫ0.62 days, 95% CI Ϫ1.12 to Ϫ0.12).
(2) Yu Xing Cao atomization versus gentamicin atomization 27 Time to relief of cough was evaluated and showed a statistically significant decrease (WMD Ϫ1.37 days, 95% CI Ϫ1.67 to Ϫ1.07). 
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FIG. 1.
Time to improvement of symptoms and signs. Except one study, 28 Chinese herbal medicines of other 11 studies appeared statistically significantly fewer time to improvement of symptoms and signs than control remedies. 28 Time to resolution of cough was evaluated and the shortening showed statistical significance (WMD Ϫ2.40 days, 95% CI Ϫ2.84 to Ϫ1.96). (4) Tan Re Qing injection versus levofloxacin 19 Time to relief of cough was evaluated and the shortening showed statistical significance (WMD Ϫ3.17 hours, 95% CI Ϫ5.95 to Ϫ0.39). 2. Fever: Data from four trials showed that the duration of fever was shorter in the Chinese herbs group than in the control group.
(1) Xiao'er Xiao Ji Zhi Ke Kou Fu Ye versus cefotaxime plus fluimucil (N-acetylcysteine) 25 Time to resolution of fever was evaluated and the decrease in time showed statistical significance (WMD Ϫ1.22 days, 95% CI Ϫ1.67 to Ϫ0.77).
(2) Yu Xing Cao atomization versus gentamicin atomization 27 Time to relief of fever was evaluated and the decrease showed statistical significance (WMD Ϫ0.92 days, 95% CI Ϫ1.03 to Ϫ0.81).
(3) Shi Wei Long Dan Hua Ke Li plus antibiotics versus antibiotics 28 Time to resolution of fever was evaluated and the decrease showed statistical significance (WMD Ϫ0.99 days, 95% CI Ϫ1.44 to Ϫ0.54).
(4) Tan Re Qing injection versus levofloxacin 19 Time to relief of fever was evaluated and the decrease showed statistical significance (WMD Ϫ32.13 hours, 95% CI Ϫ34.81 to Ϫ29.45). 3. Wheezing: Data from one trial showed that the duration of wheezing was shorter in the Chinese herbs group than in the control group.
(1) Xiao'er Xiao Ji Zhi Ke Kou Fu Ye versus cefotaxime plus fluimucil (N-acetylcysteine) 25 Time to resolution of wheezing was evaluated and the reduction showed statistical significance (WMD Ϫ0.44 days, 95% CI Ϫ0.74 to Ϫ0.14). 4. Rales: Data from two trials 25, 28 showed that the duration of rales was shorter in the Chinese herbs group than in the control group. Another trial 28 showed the opposite result.
(1) Xiao'er Xiao Ji Zhi Ke Kou Fu Ye versus cefotaxime plus fluimucil (N-acetylcysteine) 25 Time to resolution of rales was evaluated and the decrease in time showed statistical significance (WMD Ϫ1.00 days, 95% CI Ϫ1.47 to Ϫ0.53).
(2) Shi Wei Long Dan Hua Ke Li plus antibiotics versus antibiotics 28 Time to resolution of rales was evaluated and the decrease showed statistical significance (WMD Ϫ2.76 days, 95% CI Ϫ3.26 to Ϫ2.26).
(3) Yu Xing Cao atomization versus gentamicin atomization 27 Time to relief of rales was evaluated and the reduced time showed statistical significance (WMD 0.60 days, 95% CI 0.19 to 1.01).
Improvement in symptoms and signs (Fig. 2) 1. Cough: Data from two trials showed that patients with cough received greater relief in the Chinese herbs group than in the control group.
(1) Tan Re Qing injection versus levofloxacin 19 The proportion of patients with cough resolved at followup was analyzed and the positive effect of herbs showed statistical significance (RR 2.14, 95% CI 1.25 to 3.67).
(2) Shi Wei Long Dan Hua Ke Li plus antibiotics versus antibiotics 22 The proportion of patients with cough relieved by treatment was analyzed and the positive effect of herbs showed statistical significance (RR 
Adverse events
One trial 28 reported on adverse effects during treatment. One (1) patient treated with Huang Huang Lian injection complained about a skin rash, which disappeared when treatment was stopped.
DISCUSSION
Since there is no gold standard test, the diagnosis of acute bronchitis must be based on clinical assessment. All of the trials in the review included patients with recent onset of a respiratory illness with productive cough and fever and excluded patients with chronic pulmonary disease. The clinical characteristics of the enrolled patients varied but were consistent with the variety of similar definitions generally used by primary physicians. Therefore, these results appear to be generalisable to the management of acute bronchitis in community practices.
Four trials 19, [25] [26] [27] [28] reported the time to improvement of cough, fever, and rales and showed that patients treated with Chinese herbs had a shorter duration of signs and symptoms. Two trials 19, 22 reported the proportion of patients with improved signs and symptoms at follow-up and showed that Chinese herbs were beneficial for the relief of signs and symptoms.
The majority of trials reported data on physician global assessments of improvement at follow-up. Regarding ineffective rates, nine out of 13 trials showed that Chinese herbs were superior to routine treatment; and the other four trials showed a similar effect to routine treatment. In general, Chinese herbs appeared more beneficial.
In this review 12 preparations of Chinese herbs were assessed. The numbers of included trials using the same preparation were very few. In addition to the low quality of the included trials, the conclusions were inadequate. Furthermore, many trials did not give adequate information about the control group, just referring to "antibiotics," "antiviral," "antitussive," et cetera. The specific drug name and the dosages were not mentioned. For example, in three trials 22 20, 26, 28, 30 nine studies showed that significantly fewer people lacked effect than those who were treated by Chinese herbal medicines rather than control remedies.
to the intervention group and antibiotics were administered to both the intervention and control groups, but which antibiotic was used was not described. In one (1) of 14 trials adverse events were reported, in the Shuang Huang Lian injection plus penicillin-group only. 21 Some studies described any adverse events with Chinese herbs in terms of "safety" or "low side-effect," but these statements were not supported with adequate data.
The majority of studies did not give adequate methodological information. None of the studies mentioned allocation concealment, which could prevent selection bias. All trials mentioned random allocation but did not state the method used. We contacted the authors to elicit the methods used and discovered some errors.
The majority of studies were of low quality and without double-blinding, which may result in bias. Blinding was not mentioned in all of the trials. Chinese herbal preparations are usually different in terms of appearance, taste, and smell to Western medicines. Therefore, blinding was difficult. Some injection preparations, for example, Tan Re Qing injection, 20 could be blinded to patients and operator but blinding was not used. None of the studies mentioned blinding of the outcome assessors, leading to suspicion of detection bias. Publication bias may exist as all the included studies were published in Chinese and no primary article reported negative results.
The outcome definition and timing of outcome measures varied from study to study; in addition, there were only a small number of trials for each preparation. It was difficult to do a meta-analysis, which has led to some loss of information. The outcome definitions adopted by this review and used in the majority of studies were based on the period and extent of cough, fever, and other manifestations, which may lead to diversities of subjective judgement by individual physicians. There was also a loss of information from the studies that did not provide the data to fulfill the outcome criteria stipulated by this review. A more objective definition of outcome measures may be adopted in future updates of this review. The disease duration at trial entry also varied between studies.
This review may be affected by selection bias, performance bias and detection bias due to lack of allocation concealment and blinding. Meanwhile, bias may have occurred due to the limited number of small trials.
CONCLUSIONS
Implications for practice
There are insufficient quality data to recommend the routine use of Chinese herbs for acute bronchitis. The benefit found in individual studies and this systematic review could be due to publication bias and study-design limitations. In addition, the safety of Chinese herbs is unknown due to the lack of toxicological evidence on these Chinese herbs, though adverse events were rarely reported. Chinese herbs should be used carefully.
Implications for research
There is a widespread belief among Chinese clinicians and patients that Chinese herbs are effective in improving signs and symptoms of acute bronchitis. Due to the low quality of trials, this conclusion is unreliable. This demands that additional, well-designed randomised controlled trials with adequate power to provide a definitive answer need be conducted. For many Chinese researchers, allocation concealment should be emphasised and the approaches should be reported clearly. Randomisation procedure also should be described clearly in reports. Blinding should be conducted in trials on Chinese herbs, though this may be difficult. Studies should emphasise adverse effects, and more toxicological research on Chinese herbs should be conducted, which would provide important information for clinicians.
